Esperion Therapeutics (ESPR) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

ESPR Esperion Therapeutics

Watchlist

2.030
-0.010-0.49%

Close Nov 1 16:00 ET

2.040
+0.010+0.49%

Post 18:10 ET

398.34MMarket Cap-2388P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Earnings Preview: ESPR to Report Financial Results Pre-market on November 07
Moomoo NewsNov 1 21:00 ET
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
GlobeNewswireOct 31 08:00 ET
BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating
Moomoo NewsOct 28 10:31 ET · Ratings
Esperion to Report Third Quarter 2024 Financial Results on November 7
GlobeNewswireOct 24 08:00 ET
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings
Yahoo FinanceOct 17 19:02 ET
Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?
Yahoo FinanceOct 3 04:56 ET

Comments

Trytosaveabit

1 hour ago

A few PM earnings I have my eye on Thursday morning 11/7/20

$Esperion Therapeutics (ESPR.US)$ Along with this! I will also be looking towards $Wheels Up Experience (UP.US)$ & $ADC Therapeutics (ADCT.US)$ ! There is a number of others PM. But these 3 is where i will be looking a bit more intently! Hehehe. NFA Just thinking outloud

HH1000

Oct 28 09:41

$Esperion Therapeutics (ESPR.US)$ BofA Securities Maintains Esperion Therapeutics(ESPR.US) With Sell Rating
they must be shorting it lol

10xStockPicks

Oct 24 07:55

Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable

Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 million Americans take statin drugs, we see continued prescription growth & expect over 5...

+20

10xStockPicks

Oct 21 15:29

PLUG Lowered To HOLD, Losses Still Predicted In 2025. ESPR Reiterated Strong Buy, Profitable In 2025

$Plug Power (PLUG.US)$We lowered our rating to HOLD based on earnings growth is still not enough to gain profits. We believe Trump will win the 2024 election, and that will put pressure on Plug Power. End of 2025 PLUG is estimated to have a loss of ($-0.57) a share. We expect more dilution will also be needed.
Esperion $Esperion Therapeutics (ESPR.US)$ We reiterate Strong Buy rating. Esperion has...